• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

    2/15/24 10:19:33 AM ET
    $NVST
    Medical/Dental Instruments
    Health Care
    Get the next $NVST alert in real time by email
    SC 13G/A 1 EnvistaHoldingsCorp.htm r13ga29415F104-cover

    SCHEDULE 13G/A

    CUSIP No: 29415F104

    1) NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON: Lazard Asset Management LLC

    2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) x

    3) SEC USE ONLY

    4) CITIZENSHIP OR PLACE OF ORGANIZATION: Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

    5) SOLE VOTING POWER: 770,181

    6) SHARED VOTING POWER: -

    7) SOLE DISPOSITIVE POWER: 1,431,194

    8) SHARED DISPOSITIVE POWER: -

    9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON: 1,431,194

    10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o

    11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9): 0.83%

    12) TYPE OF REPORTING PERSON: IA

    Item 1(a). Name of Issuer:

    Envista Holdings Corp

    Item 1(b). Address of Issuer's Principal Executive Offices:

    200 S. KRAEMER BLVD., BLDG. E

    BREA, CALIFORNIA 92821

    Item 2(a): Name of Person Filing: Lazard Asset Management LLC

    Item 2(b): Address of Principal Business Office or, if None, Residence:

    30 Rockefeller Plaza

    New York, New York 10112

    Item 2(c): Citizenship: Delaware Limited Liability Company

    Item 2(d): Title of Class of Securities: Common Stock

    Item 2(e): CUSIP Number: 29415F104

    Item 3: If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b), check whether the person filing is a:

    o (a) Broker or Dealer Registered Under Section 15 of the Act

    x (b) Adviser registered under section 203 of the Investment Advisers Act of 1940

    Item 4: Ownership.

    1. Amount beneficially owned: 1,431,194
    2. Percent of class: 0.83%
    3. Number of shares as to which such person has:
      1. Sole power to vote or to direct the vote: 770,181
      2. Shared power to vote or to direct the vote: -
      3. Sole power to dispose or to direct the disposition of: 1,431,194
      4. Shared power to dispose or to direct the disposition of: -

    Item 5: Ownership of Five Percent or Less of a Class: Not applicable

    Item 6: Ownership of More than Five Percent on Behalf of Another Person: Not applicable

    Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company: Not applicable

    Item 8: Identification and Classification of Members of the Group: Not applicable

    Item 9: Notice of Dissolution of Group: Not applicable

    Item 10: Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

    SIGNATURE

    After reasonable inquiry and to the best knowledge and belief of the undersigned, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

    Date: February 14, 2024

    _________________________

    Nargis Hilal

    Chief Compliance Officer and Counsel

    Get the next $NVST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVST

    DatePrice TargetRatingAnalyst
    12/4/2024$20.00Underperform
    Mizuho
    10/31/2024$16.00 → $23.00Underperform → Market Perform
    Leerink Partners
    10/8/2024$20.00Equal Weight
    Wells Fargo
    8/8/2024$23.00 → $16.00Overweight → Neutral
    JP Morgan
    4/26/2024$33.00 → $21.00Overweight → Equal-Weight
    Morgan Stanley
    2/26/2024$19.00Underperform
    Leerink Partners
    2/9/2024$30.00 → $23.00Buy → Hold
    Jefferies
    2/8/2024Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $NVST
    SEC Filings

    See more
    • SEC Form 10-Q filed by Envista Holdings Corporation

      10-Q - Envista Holdings Corp (0001757073) (Filer)

      5/1/25 4:17:13 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Holdings Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Envista Holdings Corp (0001757073) (Filer)

      5/1/25 4:10:29 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Envista Holdings Corporation

      DEFA14A - Envista Holdings Corp (0001757073) (Filer)

      4/24/25 4:14:05 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Envista Holdings Corporation

      SC 13G - Envista Holdings Corp (0001757073) (Subject)

      11/8/24 12:09:03 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Envista Holdings Corporation (Amendment)

      SC 13G/A - Envista Holdings Corp (0001757073) (Subject)

      2/15/24 10:19:33 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Envista Holdings Corporation

      SC 13G - Envista Holdings Corp (0001757073) (Subject)

      2/14/24 4:08:38 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Envista Reports First Quarter 2025 Results

      BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

      5/1/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Schedules First Quarter 2025 Earnings Call

      BREA, Calif., April 8, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2025 on Thursday, May 1, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You ca

      4/8/25 4:15:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Smile Project Donates $1.8 Million in 2024

      BREA, Calif., Feb. 25, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") proudly announced that in 2024, the Envista Smile Project (Smile Project) contributed $1.8 million to further its mission of enhancing oral health accessibility for underserved communities. Since its inception in 2021, the Envista Smile Project has delivered over $4.2 million in dental goods and services, positively impacting approximately 32,000 individuals worldwide. In 2024, the Envista Smile Project: Supplied free dental care to more than 787 patients in the Dominican Republic.

      2/25/25 4:10:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Financials

    Live finance-specific insights

    See more
    • Envista Reports First Quarter 2025 Results

      BREA, Calif., May 1, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended March 28, 2025. "In the first quarter, Envista delivered results in line with our expectations building on the momentum established across the second half of 2024," said Paul Keel, CEO. "We continued to drive improvements across our three priority areas of growth, operations, and people. This was a solid start to the year, and we are maintaining our 2025 guidance." Q1 2025 financial highlights: Sales were $617 million, with core sales increasing 0.2%

      5/1/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Schedules First Quarter 2025 Earnings Call

      BREA, Calif., April 8, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) ("Envista") will report financial results for its first quarter 2025 on Thursday, May 1, 2025. Envista will discuss these results on a conference call on the same day beginning at 2:00 PM PT and lasting approximately one hour.  The call and the accompanying slide presentation will be webcast on the "Investors" section of Envista's website, www.envistaco.com. A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available for one year. You ca

      4/8/25 4:15:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista Reports Fourth Quarter 2024 Results

      BREA, Calif., Feb. 5, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced results for the quarter ended December 31, 2024. "In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact," said Paul Keel, Envista's CEO.  "2024 was a transition year for our company.  After a challenging first half, we took actions over the last two quarters to position ourselves for improved performance moving forward.  While we still have much more to do, we're encourag

      2/5/25 4:05:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Keel Paul A bought $506,100 worth of shares (30,000 units at $16.87), increasing direct ownership by 8% to 402,605 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/14/24 4:40:20 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Hammes Eric D. bought $400,608 worth of shares (24,532 units at $16.33) (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      8/13/24 6:01:10 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Conley Eric bought $50,015 worth of shares (2,185 units at $22.89), increasing direct ownership by 5% to 47,376 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      11/20/23 5:49:32 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Leadership Updates

    Live Leadership Updates

    See more
    • QuidelOrtho Announces Appointment of Two Independent Directors to its Board

      Veteran Healthcare CEOs John R. Chiminski and R. Scott Huennekens Bring Deep Industry Experience, Operational Expertise and Financial Acumen to the QuidelOrtho Board QuidelOrtho Corporation (NASDAQ:QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced the appointments of John R. Chiminski and R. Scott Huennekens to its board of directors (the "Board"), effective December 6, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241210769572/en/R. Scott Huennekens (Photo: Business Wire) T

      12/10/24 7:00:00 AM ET
      $CTLT
      $HYPR
      $NVST
      $QDEL
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments
    • Compass Diversified Announces Stephen Keller as Chief Financial Officer

      WESTPORT, Conn., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE:CODI) ("CODI" or the "Company"), an owner of leading middle market businesses, announced today that Stephen Keller has been appointed as the Company's Chief Financial Officer (CFO), effective August 31, 2024. He will be replacing Ryan Faulkingham, who has served as the Company's CFO since July 2013 and is departing the Company effective August 30, 2024. Mr. Faulkingham will continue to serve in an advisory capacity in order to facilitate a seamless transition. In his new role, Mr. Keller will lead CODI's finance organization, including accounting, planning, treasury, tax, reporting, and investor relations. He b

      8/26/24 6:00:00 AM ET
      $AVY
      $CODI
      $NVST
      Containers/Packaging
      Consumer Discretionary
      Home Furnishings
      Medical/Dental Instruments
    • Envista Holdings Corporation Announces Key Leadership Appointments

      BREA, Calif., July 15, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE:NVST) today announced the following key leadership appointments: Eric Hammes joins Envista as Chief Financial OfficerStefan Nilsson joins Envista as President, Nobel BiocareVeronica Acurio joins Envista as President, Ormco"It is a pleasure to welcome this trio of successful leaders to Envista," said Paul Keel, Chief Executive Officer. "Each brings experience in dental along with a proven track record of continuous improvement, leading with purpose, and creating value for all stakeholders. Today's an

      7/15/24 4:10:00 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Kaabi Faez C covered exercise/tax liability with 4,319 shares and was granted 9,685 shares, increasing direct ownership by 12% to 49,996 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:45 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • SVP, Strategy & Bus. Dev. Reis Mischa covered exercise/tax liability with 3,813 shares and was granted 8,475 shares, increasing direct ownership by 11% to 47,382 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:34 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Chief Executive Officer Keel Paul A was granted 65,830 shares, increasing direct ownership by 19% to 414,439 units (SEC Form 4)

      4 - Envista Holdings Corp (0001757073) (Issuer)

      2/27/25 5:27:24 PM ET
      $NVST
      Medical/Dental Instruments
      Health Care

    $NVST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mizuho initiated coverage on Envista with a new price target

      Mizuho initiated coverage of Envista with a rating of Underperform and set a new price target of $20.00

      12/4/24 7:46:09 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Envista upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Envista from Underperform to Market Perform and set a new price target of $23.00 from $16.00 previously

      10/31/24 6:27:39 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Envista with a new price target

      Wells Fargo initiated coverage of Envista with a rating of Equal Weight and set a new price target of $20.00

      10/8/24 7:32:45 AM ET
      $NVST
      Medical/Dental Instruments
      Health Care